Dominique Charmot
Overview
Explore the profile of Dominique Charmot including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
267
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jacobs J, Leadbetter M, Bell N, Koo-McCoy S, Carreras C, He L, et al.
ACS Med Chem Lett
. 2022 Jul;
13(7):1043-1051.
PMID: 35859876
We present herein the design, synthesis, and optimization of gut-restricted inhibitors of Na/H exchanger isoform 3 (NHE3). NHE3 is predominantly expressed in the kidney and gastrointestinal tract where it acts...
2.
Chen T, Reich N, Bell N, Finn P, Rodriguez D, Kohler J, et al.
J Med Chem
. 2018 Aug;
61(17):7589-7613.
PMID: 30141927
Bile acid signaling and metabolism in the gastrointestinal tract have wide-ranging influences on systemic disease. G protein-coupled bile acid receptor 1 (GPBAR1, TGR5) is one of the major effectors in...
3.
Kozuka K, He Y, Koo-McCoy S, Kumaraswamy P, Nie B, Shaw K, et al.
Stem Cell Reports
. 2017 Nov;
9(6):1976-1990.
PMID: 29153987
We describe the development and characterization of a mouse and human epithelial cell monolayer platform of the small and large intestines, with a broad range of potential applications including the...
4.
Johansson S, Leonsson-Zachrisson M, Knutsson M, Spencer A, Labonte E, Deshpande D, et al.
Clin Pharmacol Drug Dev
. 2016 Sep;
6(5):448-456.
PMID: 27654985
Tenapanor (RDX5791, AZD1722), a first-in-class small molecule with minimal systemic availability, is an inhibitor of the sodium/hydrogen exchanger isoform 3. Tenapanor acts locally in the gut, where it reduces absorption...
5.
Labonte E, Carreras C, Leadbetter M, Kozuka K, Kohler J, Koo-McCoy S, et al.
J Am Soc Nephrol
. 2014 Nov;
26(5):1138-49.
PMID: 25404658
In CKD, phosphate retention arising from diminished GFR is a key early step in a pathologic cascade leading to hyperthyroidism, metabolic bone disease, vascular calcification, and cardiovascular mortality. Tenapanor, a...
6.
Spencer A, Labonte E, Rosenbaum D, Plato C, Carreras C, Leadbetter M, et al.
Sci Transl Med
. 2014 Mar;
6(227):227ra36.
PMID: 24622516
The management of sodium intake is clinically important in many disease states including heart failure, kidney disease, and hypertension. Tenapanor is an inhibitor of the sodium-proton (Na(+)/H(+)) exchanger NHE3, which...
7.
Charmot D
Curr Pharm Des
. 2012 Feb;
18(10):1434-45.
PMID: 22300258
Non-systemic drugs act within the intestinal lumen without reaching the systemic circulation. The first generation included polymeric resins that sequester phosphate ions, potassium ions, or bile acids for the treatment...